Join Conscio Group upcoming webinar on December 12 at 2:00 PM CET (expected length up to 2 hours), where industry experts will discuss the latest trends in regulation, R&D and clinical testing. In our session we will particularly explore potential regulatory changes regarding the waiver of Phase 3 efficacy studies.

Topics include:

  • Navigating Biosimilar Regulations: Evolution, Challenges, and Future Directions
  • Common pitfalls on the path from R&D to biotech product commercialization
  • Strategies for successful bioassay transfer and validation – the importance of standardization

Speakers: Elena Guillen Benitez, MD, PhD from Leiden University Medical Center, Martin Baur from Midas Pharma, and Klemens Weitenthaler from Conscio Group.

Moderator: Stephan Holl, CEO Conscio Group

Gain insider knowledge on the biosimilar industry – register here!

If you would like to view the recording of the webinar, please contact us today and we will be happy to give you exclusive access to it on our YouTube channel.

Additional News

  • 9 July 2025

    HER-096: A possible breakthrough in Parkinson’s disease treatment

    This testimonial highlights our collaboration with Herantis Pharma on the analytical development and nonclinical support for HER-096, a promising candidate in the fight against Parkinson’s disease.

  • 9 June 2025

    Ensuring Success in Buccal Film Development: The Midazolam Film Case Study

    Fast, Simple, Effective: Unlocking the Potential of Midazolam Films

  • 15 May 2025

    From Analytical Similarity to Clinical Data: Tailoring Evidence for Biosimilar Approval

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar.

ALL POSTS